Showing 4981-4990 of 6036 results for "".
- LumiThera Completes Patient Enrollment in LIGHTSITE III Clinical Study to Treat Dry AMDhttps://modernod.com/news/lumithera-completes-patient-enrollment-in-the-lightsite-iii-clinical-study-to-treat-dry-amd/2478882/LumiThera announced it has completed enrollment in its multicenter US clinical study in non-neovascular (dry) age-related macular degeneration (AMD) patients. The randomized, multicenter study, LIGHTSITE III, enrolled the last patient at the Byers Eye Insti
- LION Eye Group Collaborates with OCLI-Spectrum Vision Partnershttps://modernod.com/news/lion-eye-group-collaborates-with-ocli-spectrum-vision-partners/2478878/New York-based LION Eye Group announces it has entered into a collaborative agreement with OCLI-Spectrum Vision Partners (OCLI) for integrated eye care. Terms of the deal were not disclosed. “The collaboration was the result of LION’s effort to engage in high quality med
- New World Medical’s Next-Generation KDB GLIDE Now Commercially Availablehttps://modernod.com/news/new-world-medicals-next-generation-kdb-glide-now-commercially-available/2478880/New World Medical announced the launch of the KDB GLIDE device for advanced excisional goniotomy treatment of glaucoma. The KDB GLIDE, which was registered with the FDA in October 2020, is now commercially available to ophthalmic surgeons across the US looking for refined, precise performance dur
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- Regenxbio Announces Additional Positive Interim Phase 1/2a and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-additional-positive-interim-phase-1-2a-and-long-term-follow-up-data-of-rgx-314-for-the-treatment-of-wet-amd/2478873/Regenxbio reported additional positive interim data from Cohorts 4 and 5 of its RGX-314 phase 1/2a trial for the treatment of wet age-related macular degeneration (AMD), and Cohort 3 of its Long-Term Follow-Up (LTFU) study. RGX-314 is a potential best-in-class, one-time gene therapy for the treat
- Inspecs Launches Sustainable Botaniq Eyewear Collectionhttps://modernod.com/news/inspecs-launches-sustainable-botaniq-eyewear-collection/2478870/Inspecs has launched its own sustainable eyewear range called Botaniq. The Botaniq collection, which will initially launch with 48 SKUs across 16 styles, is designed by a team of in-house technical experts at Inspecs, using biodegradeable eyewear materials as a direct response to consumer demand
- Gyroscope Therapeutics Announces Positive Interim Data from Phase 1 FOCUS Trial of Investigational Gene Therapy GT005https://modernod.com/news/gyroscope-therapeutics-announces-positive-interim-data-from-phase-1-focus-trial-of-investigational-gene-therapy-gt005/2478865/Gyroscope Therapeutics announced positive interim safety, protein expression and biomarker data from the ongoing open-label phase 1/2 FOCUS clinical trial of its investigational gene therapy, GT005, in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Inte
- Genentech: New Phase 3 Data Show Faricimab the First Investigational Injectable Eye Medicine to Extend Time Between Treatment to Up to 4 Monthshttps://modernod.com/news/new-phase-3-data-show-genentechs-faricimab-is-the-first-investigational-injectable-eye-medicine-to-extend-time-between-treatment-to-up-to-4-months/2478862/Genentech announced detailed results from four phase 3 studies of its investigational bispecific antibody, faricimab, for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The studies consistently showed that faricimab, given at intervals of up
- Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry AMD in Patients with High-Risk Genetic Variantshttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-trial-of-gem103-in-dry-amd-in-patients-with-high-risk-genetic-variants/2478851/Gemini Therapeutics announced the completion of enrollment in its phase 2a “ReGAtta” study. ReGAtta is a dose escalation trial of GEM103, a recombinant human complement factor H (CFH), in dry AMD patients with CFH loss-of-function gene variants. The trial is designed to evaluate safet
- Johnson & Johnson Vision Celebrates 20 Years of See More Campaign and Global Patient Story Searchhttps://modernod.com/news/johnson-johnson-vision-celebrates-20-years-of-see-more-campaign-and-global-patient-story-search/2478846/Johnson & Johnson Vision announced a month-long celebration of the 20th Anniversary of the Tecnis platform, the proprietary combination of materials and design on which Johnson & Johnson Vision IOLs are built. Twenty years ago, a team of researchers and innovators created Tecnis, setting